Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276692 | 1.00 | TRPA1 (0.30) | TRPA1MAPK1 | |
| SCHEMBL3101806 | 0.71 | — | — | |
| SCHEMBL28573514 | 0.69 | — | — | |
| SCHEMBL9860573 | 0.69 | — | — | |
| SCHEMBL15912583 | 0.69 | — | — | |
| SCHEMBL9860569 | 0.69 | — | — | |
| SCHEMBL17363190 | 0.69 | — | — | |
| SCHEMBL3141430 | 0.67 | — | — | |
| SCHEMBL13040926 | 0.67 | — | — | |
| SCHEMBL3141436 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856026-A1 | PURIFICATION PROCESS | Novartis AG (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006089746-A1 | PURIFICATION PROCESS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | claimed |
| CN-114380696-B | Preparation method of terbinafine hydrochloride | 山东诚汇双达药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-114380696-A | Preparation method of terbinafine hydrochloride | 山东诚汇双达药业有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20100087545-A1 | PURIFICATION PROCESS | BEUTLER ULRICH | 2010-04-08 | — | — | US | disclosed |
| US-20100087545-A1 | PURIFICATION PROCESS | BEUTLER ULRICH | 2010-04-08 | — | — | US | disclosed |
| EP-2121572-A2 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | Auspex Pharmaceuticals Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073863-A2 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1236709-B1 | A process for the preparation of terbinafine | DIPHARMA FRANCIS SRL (IT) | 2007-12-05 | — | — | EP | disclosed |
| EP-1856026-A1 | PURIFICATION PROCESS | Novartis AG (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20050197512-A1 | Purification process | BEUTLER ULRICH (CH) | 2005-09-08 | — | — | US | disclosed |
| US-6515181-B2 | Reacting tert-butylacetylene with (3-chloro-2-propenyl)-n-methyl-1-naphthalene methanamine in the presence of copper (I) salts and of a base, in the absence of palladium | DIPHARMA S.P.A. (IT) | 2003-02-04 | — | — | US | disclosed |
| US-20020123651-A1 | Process for the preparation of terbinafine | DIPHARMA S.P.A. (IT) | 2002-09-05 | — | — | US | disclosed |
| EP-1236709-A2 | A process for the preparation of terbinafine | Dinamite Dipharma S.p.A. (in abbreviated form Dipharma S.p.A.) (IT) | 2002-09-04 | — | — | EP | disclosed |
| US-5817875-A | Methods for the manufacture of terbinafine | KARIMIAN KHASHAYAR (CA) | 1998-10-06 | — | — | US | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-4751245-A | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E. R. SQUIBB & SONS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0251574-A2 | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E.R. Squibb & Sons, Inc. (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087545-A1 | PURIFICATION PROCESS | SLC6A12, SLC28A1, SLC6A6 | TRPA1 265/4885MAPK1 135/4885 |
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | UGT1A7, UGT2B7, UGT1A10 | TRPA1 1653/4885MAPK1 3151/4885 |
| US-20020123651-A1 | Process for the preparation of terbinafine | CYP2F1, TBCB, TERT | TRPA1 4437/4885MAPK1 725/4885 |
| US-20050197512-A1 | Purification process | SLC6A12, SLC28A1, SLC6A6 | TRPA1 265/4885MAPK1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.